AstraZeneca's Obesity Pills Revealed Positive Result In Phase I Trials
8 hours ago · Latest News. Stock Market. Originals. The Morning Brief. Premium News. Economics. Housing. Earnings. Tech. ... AZD5004 is an oral GLP-1 receptor blocker and is licensed in 2023 from Shanghai-based ...
AstraZeneca sees progress in obesity drug trials, highlights new …
11 hours ago · AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 agonist AZD5004, which achieved a 5.8% weight reduction over four weeks in type-2 diabetes patients. AZD5004, advancing to Phase IIb, faces dose-related nausea but showed promising tolerability. AstraZeneca aims to compete with market leaders like Novo Nordisk and Eli ...
AstraZeneca Bolsters Obesity Pipeline With Promising Early
13 hours ago · Leading the pharma’s weight loss program is AZD5004, a small molecule oral GLP-1 receptor blocker licensed in November 2023 from Shanghai-based biotech Eccogene. At ObesityWeek, AstraZeneca unveiled early data for AZD5004, touting a clean safety profile for the investigational pill. ... BioSpace is the digital hub for life science news and ...
AstraZeneca Says Obesity Pill Shows Minimal Side Effects
1 day ago · The Anglo-Swedish drugmaker's closely watched weight loss pill, AZD5004, showed 5.8% weight loss after four weeks of treatment among patients with type 2 diabetes, it said Monday during the ...
AstraZeneca says experimental obesity pill safe in early-stage trial
AstraZeneca's shares rose as much as 2.9% after the data release, before paring gains. At 1720 GMT they were up 0.2%. When AstraZeneca announced it had licensed the once-daily pill, called AZD5004 ...
AstraZeneca's Obesity Pills Revealed Positive Result In Phase I
7 hours ago · Summary. In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (AZN, Financial) revealed positive initial clinical trial results for its obesity drug candidate the oral GLP-1 pill AZD5004 and a selective amylin agonist AZD6234. They also try to make a combination drug experiment to offer even more ...
Eccogene Receives Milestone Payment of $60 Million from
Oct 23, 2024 · We are pleased to see ECC5004/AZD5004 – our internally discovered oral small molecule GLP-1 receptor agonist – advancing into Phase 2b clinical trials for obesity and type 2 diabetes.
Effects of AZD5004 in adults who are living with obesity or …
A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living with Obesity or Overweight with Comorbidity.
AstraZeneca licenses novel agent for the treatment of …
Nov 9, 2023 · AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions.
Eccogene Receives Milestone Payment of $60 Million from
Oct 24, 2024 · Eccogene’s oral small molecule GLP-1 receptor agonist, ECC5004/AZD5004, is a potentially best-in-class asset, which was licensed to AstraZeneca. Eccogene also has clinical programs underway that target THR-β and SSAO, as well as preclinical programs targeting proven pathways, such as GIP.
- Some results have been removed